Fedratinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-FEDRATINIB |
|---|---|
| Type | Drug |
| Aliases | InrebicФедратиніб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-PMF |
| Sources | SRC-COMFORT-I-VERSTOVSEK-2012 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | JAK2 inhibitor (selective for JAK2 over JAK1) |
|---|---|
| Mechanism | Selective JAK2 inhibitor with FLT3 activity. Active in MF after ruxolitinib failure / intolerance. Boxed warning for Wernicke encephalopathy (thiamine deficiency). |
| Typical dosing | MF: 400 mg PO once daily with food. Hold for severe diarrhea / nausea. Mandatory thiamine supplementation + screening for thiamine deficiency before each cycle. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Wernicke encephalopathy / thiamine deficiency — fatal if untreated; mandatory thiamine before + during therapy
Notes
2L MF (post-ruxolitinib failure or intolerance); FREEDOM-2 confirmed spleen response benefit. Take with food to reduce GI toxicity. Mandatory thiamine measurement + supplementation before each cycle. NOT registered in Ukraine.
Used By
Regimens
REG-FEDRATINIB-PMF- Fedratinib (Inrebic) for ruxolitinib-resistant / intolerant PMF